Life ScienceCompany
Dechra Pharmaceuticals M&A Summary
Dechra Pharmaceuticals has acquired 16 companies of its own, including 2 in the last 5 years. A total of 4 acquisitions came from private equity firms. It has also divested 1 asset.
Dechra Pharmaceuticals’ largest acquisition to date was in 2024, when it acquired Invetx for $520M. Dechra Pharmaceuticals has acquired in 5 different US states, and 8 countries. The Company’s most targeted sectors include life science (88%) and consumer products (7%).
Dechra Pharmaceuticals Ownership
Who owns Dechra Pharmaceuticals?
Dechra Pharmaceuticals is owned by ADIA and EQT. It was acquired on July 20, 2023.
Is Dechra Pharmaceuticals PE-backed?
Yes. Dechra Pharmaceuticals is owned by private equity investors ADIA and EQT.
Dechra Pharmaceuticals Business Overview
Where is Dechra Pharmaceuticals headquartered?
Dechra Pharmaceuticals is headquartered in Northwich, United Kingdom.
What is Dechra Pharmaceuticals’ revenue?
Dechra Pharmaceuticals disclosed revenue of 682M GBP for 2022 and 608M GBP for 2021.
What sector is Dechra Pharmaceuticals in?
Dechra Pharmaceuticals is a life science company.
When was Dechra Pharmaceuticals founded?
Dechra Pharmaceuticals was founded in 1997.
M&A Summary
-
M&A Total Activity17
- M&A Buy Activity16
- M&A Sell Activity1
- Total Sectors Invested 3
- Total Countries Invested 8
- M&A Buy/Sell Connections 6
- M&A Advisors 3
Unlimited Searches
